{"organizations": [], "uuid": "c73549223fbe99a77d418c02f61631b81109f06b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-altimmune-announces-positive-data/brief-altimmune-announces-positive-data-from-its-phase-2a-study-of-nasovax-intranasal-influenza-vaccine-idUSASC09TRI", "country": "US", "domain_rank": 408, "title": "BRIEF-Altimmune Announces Positive Data From Its Phase 2A Study Of Nasovax Intranasal Influenza Vaccine", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-27T15:07:00.000+03:00", "replies_count": 0, "uuid": "c73549223fbe99a77d418c02f61631b81109f06b"}, "author": "", "url": "https://www.reuters.com/article/brief-altimmune-announces-positive-data/brief-altimmune-announces-positive-data-from-its-phase-2a-study-of-nasovax-intranasal-influenza-vaccine-idUSASC09TRI", "ord_in_thread": 0, "title": "BRIEF-Altimmune Announces Positive Data From Its Phase 2A Study Of Nasovax Intranasal Influenza Vaccine", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "nasovax intranasal influenza vaccine", "sentiment": "negative"}, {"name": "intranasal influenza vaccine reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "altimmune inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 08 PM / Updated 23 minutes ago BRIEF-Altimmune Announces Positive Data From Its Phase 2A Study Of Nasovax Intranasal Influenza Vaccine Reuters Staff 1 Min Read March 27 (Reuters) - Altimmune Inc: * ALTIMMUNE ANNOUNCES POSITIVE DATA FROM ITS PHASE 2A STUDY OF NASOVAX INTRANASAL INFLUENZA VACCINE AND PROVIDES AN UPDATE ON ITS PHASE 1B STUDY OF HEPTCELL TARGETED IMMUNOTHERAPY IN CHRONIC HEPATITIS B INFECTION * ALTIMMUNE INC - HEPTCELL VACCINE WAS WELL TOLERATED BUT T-CELL IMMUNOGENICITY RESULTS WERE INCONCLUSIVE * ALTIMMUNE - RESULTS FROM NASOVAX INTRANASAL FLU VACCINE PHASE 2A STUDY IN 60 HEALTHY INDIVIDUALS SHOWED 100% SEROPROTECTION IN MID- & HIGH-DOSE GROUPS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)", "external_links": [], "published": "2018-03-27T15:07:00.000+03:00", "crawled": "2018-03-27T15:36:17.003+03:00", "highlightTitle": ""}